$783 Million is the total value of Vivo Capital, LLC's 45 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ASND | Ascendis Pharma A/Sadr | $135,752,000 | -11.6% | 2,166,832 | 0.0% | 17.34% | +12.0% | |
| CRNX | Crinetics Pharmaceuticals Inc | $113,727,000 | +4.7% | 3,792,169 | 0.0% | 14.52% | +32.6% | |
| SVA | Sinovac Biotech Ltd. | $40,946,000 | -8.9% | 5,900,000 | 0.0% | 5.23% | +15.4% | |
| ARWR | Arrowhead Pharmaceuticals Inc | $28,920,000 | -35.2% | 2,328,475 | 0.0% | 3.69% | -17.9% | |
| KALV | KalVista Pharmaceuticals Inc. | $26,843,000 | -10.7% | 1,359,149 | 0.0% | 3.43% | +13.2% | |
| FIXX | Homology Medicines, Inc. | $25,932,000 | -2.2% | 1,159,742 | 0.0% | 3.31% | +24.0% | |
| KDMN | Kadmon Holdings Inc | $21,745,000 | -37.7% | 10,454,545 | 0.0% | 2.78% | -21.1% | |
| EIGR | Eiger BioPharmaceuticals Inc | $18,199,000 | -15.3% | 1,791,257 | 0.0% | 2.32% | +7.3% | |
| MNLO | Menlo Therapeutics Inc. | $16,526,000 | -58.2% | 4,011,236 | 0.0% | 2.11% | -47.0% | |
| MEIP | MEI Pharma Inc | $15,254,000 | -38.7% | 5,778,106 | 0.0% | 1.95% | -22.4% | |
| VRNA | Verona Pharma PLCads | $13,437,000 | -28.1% | 1,492,951 | 0.0% | 1.72% | -8.8% | |
| ACRS | Aclaris Therapeutics, Inc. | $12,173,000 | -49.1% | 1,647,214 | 0.0% | 1.56% | -35.5% | |
| OBSV | Obseva SA | $11,864,000 | -29.8% | 937,147 | 0.0% | 1.52% | -11.0% | |
| Nabriva Therapeutics AG | $9,664,000 | -45.9% | 6,619,190 | 0.0% | 1.23% | -31.5% | ||
| ZYME | Zymeworks Inc | $9,104,000 | -6.5% | 620,134 | 0.0% | 1.16% | +18.6% | |
| XENE | Xenon Pharmaceuticals Inc | $8,869,000 | -52.2% | 1,405,476 | 0.0% | 1.13% | -39.4% | |
| AUPH | Aurinia Pharmaceuticals Inc. | $8,275,000 | +2.7% | 1,213,290 | 0.0% | 1.06% | +30.2% | |
| SLNO | Soleno Therapeutics, Inc. | $7,455,000 | -20.8% | 4,359,683 | 0.0% | 0.95% | +0.3% | |
| KNSA | Kiniksa Pharmaceuticals | $7,440,000 | +10.2% | 264,878 | 0.0% | 0.95% | +39.5% | |
| CBAY | Cymabay Therapeutics Inc | $7,130,000 | -29.0% | 906,000 | 0.0% | 0.91% | -10.0% | |
| KALA | Kala Pharmaceuticals, Inc. | $5,100,000 | -50.5% | 1,043,020 | 0.0% | 0.65% | -37.3% | |
| ZGNX | Zogenix, Inc. | $3,828,000 | -26.5% | 105,000 | 0.0% | 0.49% | -6.9% | |
| SRRA | Sierra Oncology, Inc | $3,219,000 | -22.3% | 2,438,270 | 0.0% | 0.41% | -1.7% | |
| GNCA | Genocea Biosciences Inc | $2,346,000 | -63.2% | 8,180,000 | 0.0% | 0.30% | -53.3% | |
| BPMX | BioPharmX Corporation | $1,740,000 | -43.2% | 16,128,515 | 0.0% | 0.22% | -28.2% | |
| AGRX | Agile Therapeutics, Inc. | $872,000 | +57.1% | 1,513,975 | 0.0% | 0.11% | +98.2% | |
| TRVN | Trevena, Inc. | $743,000 | -79.7% | 1,728,000 | 0.0% | 0.10% | -74.3% | |
| AKTX | Akari Therapeutics Plcadr | $543,000 | -38.6% | 345,850 | 0.0% | 0.07% | -22.5% | |
| SNSS | Sunesis Pharmaceuticals, Inc. | $81,000 | -79.3% | 195,474 | 0.0% | 0.01% | -74.4% | |
| SLNOW | Soleno Therapeutics, Inc.warrant | $19,000 | -17.4% | 188,772 | 0.0% | 0.00% | 0.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 29 | Q3 2023 | 33.5% |
| CODEXIS INC | 29 | Q3 2023 | 8.0% |
| ASCENDIS PHARMA A/S | 25 | Q3 2022 | 24.0% |
| KALVISTA PHARMACEUTICALS INC | 25 | Q3 2023 | 3.9% |
| Verona Pharma PLC ADR | 24 | Q3 2023 | 7.6% |
| AMYRIS INC | 23 | Q3 2023 | 8.8% |
| EIGER BIOPHARMACEUTICALS INC | 23 | Q1 2022 | 8.7% |
| Zai Lab Ltd ADR | 22 | Q3 2023 | 1.8% |
| Arrowhead Pharmaceuticals Inc | 21 | Q3 2023 | 6.9% |
| HOMOLOGY MEDICINES INC | 21 | Q3 2023 | 3.7% |
View Vivo Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SINOVAC BIOTECH LTDSold out | August 27, 2018 | 0 | 0.0% |
View Vivo Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-22 |
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-08 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Vivo Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.